S&P Futures
5,903.25 -2.75 (-0.05%) Dow Futures
43,544.00 +26.00 (+0.06%) Nasdaq Futures
20,446.75 -36.75 (-0.18%) Russell 2000 Futures
2,292.90 +1.70 (+0.07%) Crude Oil
69.67 +0.45 (+0.65%) Gold
2,741.10 +11.10 (+0.41%)
Basilea Pharmaceutica AG (BSLN.SW)
- GlobeNewswire
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has initiated the Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC) phase 3 study. This registrational study evaluates the efficacy and safety of Basilea’s broad-spectrum antifungal fosmanogepix in the treatment of adu
- GlobeNewswire
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for potential funding of up to approximately USD 268 million to develop antifungal and antibacterial assets Increasing FY 2024 financial guidance on total revenue, operating result and net profit Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 19, 2024 Basilea Pharmaceutica Ltd, Al
